 Tissue Plasminogen Activator
"Tissue Plasminogen Activator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.
| Descriptor ID |
D010959
|
| MeSH Number(s) |
D08.811.277.656.300.760.875 D08.811.277.656.959.350.875 D12.776.124.125.662.768 D23.119.970
|
| Concept/Terms |
Tissue Plasminogen Activator- Tissue Plasminogen Activator
- Plasminogen Activator, Tissue
- Tissue Activator D-44
- Tissue Activator D 44
- Tisokinase
- Tissue-Type Plasminogen Activator
- Tissue Type Plasminogen Activator
- TTPA
- T-Plasminogen Activator
- T Plasminogen Activator
- Alteplase
- Plasminogen Activator, Tissue-Type
- Plasminogen Activator, Tissue Type
Actilyse- Actilyse
- Lysatec rt-PA
- Lysatec rt PA
- Lysatec rtPA
|
Below are MeSH descriptors whose meaning is more general than "Tissue Plasminogen Activator".
Below are MeSH descriptors whose meaning is more specific than "Tissue Plasminogen Activator".
This graph shows the total number of publications written about "Tissue Plasminogen Activator" by people in this website by year, and whether "Tissue Plasminogen Activator" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 3 | 3 | 6 | | 1998 | 2 | 2 | 4 | | 2002 | 0 | 1 | 1 | | 2003 | 2 | 1 | 3 | | 2004 | 1 | 0 | 1 | | 2005 | 5 | 1 | 6 | | 2006 | 4 | 0 | 4 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 0 | 2 | | 2009 | 5 | 2 | 7 | | 2011 | 3 | 3 | 6 | | 2012 | 2 | 0 | 2 | | 2013 | 4 | 2 | 6 | | 2014 | 5 | 3 | 8 | | 2015 | 12 | 2 | 14 | | 2016 | 1 | 1 | 2 | | 2017 | 7 | 2 | 9 | | 2018 | 2 | 4 | 6 | | 2019 | 2 | 2 | 4 | | 2020 | 7 | 2 | 9 | | 2021 | 5 | 2 | 7 | | 2022 | 3 | 5 | 8 | | 2023 | 1 | 11 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Tissue Plasminogen Activator" by people in Profiles.
-
Park AJ, Garcia VP, Greiner JJ, Berry AR, Cardenas HL, Wegerson KN, Stauffer B, DeSouza CA. Development of a Hypercoagulable-Hypofibrinolytic State Early After Spinal Cord Injury. Arch Phys Med Rehabil. 2024 05; 105(5):843-849.
-
Navi BB, Bach I, Czap AL, Wang M, Yamal JM, Jacob AP, Parker SA, Rajan SS, Mir S, Sherman C, Willey JZ, Saver JL, Gonzalez MO, Singh N, Jones WJ, Ornelas D, Gonzales NR, Alexandrov AW, Alexandrov AV, Nour M, Spokoyny I, Mackey J, Collins SQ, Silnes K, Fink ME, English J, Barazangi N, Bratina PL, Volpi J, Rao CPV, Griffin L, Persse D, Grotta JC. Strokes Averted by Intravenous Thrombolysis: A Secondary Analysis of a Prospective, Multicenter, Controlled Trial of Mobile Stroke Units. Ann Neurol. 2024 Feb; 95(2):347-361.
-
Moore HB, LaRiviere W, Rodriguez I, Brown K, Hadley K, Pomposelli JJ, Adams MA, Wachs ME, Conzen KD, Kennealey PT, Kaplan B, Pomfret EA, Nydam TL. Early predictors of prolonged intensive care utilization following liver transplantation. Am J Surg. 2023 12; 226(6):829-834.
-
Pirlog BO, Jacob AP, Rajan SS, Yamal JM, Parker SA, Wang M, Bowry R, Czap A, Bratina PL, Gonzalez MO, Singh N, Zou J, Gonzales NR, Jones WJ, Alexandrov AW, Alexandrov AV, Navi BB, Nour M, Spokoyny I, Mackey J, Silnes K, Fink ME, Pisarro Sherman C, Willey J, Saver JL, English J, Barazangi N, Ornelas D, Volpi J, Pv Rao C, Griffin L, Persse D, Grotta JC. Outcomes of patients with pre-existing disability managed by mobile stroke units: A sub-analysis of the BEST-MSU study. Int J Stroke. 2023 Dec; 18(10):1209-1218.
-
Coleman JR, D'Alessandro A, LaCroix I, Dzieciatkowska M, Lutz P, Mitra S, Gamboni F, Ruf W, Silliman CC, Cohen MJ. A metabolomic and proteomic analysis of pathologic hypercoagulability in traumatic brain injury patients after dura violation. J Trauma Acute Care Surg. 2023 12 01; 95(6):925-934.
-
Cardenas HL, Evanoff NG, Fandl HK, Berry AR, Wegerson KN, Ostrander EI, Greiner JJ, Dufresne SR, Kotlyar M, Dengel DR, DeSouza CA, Garcia VP. Endothelial-derived extracellular vesicles associated with electronic cigarette use impair cerebral microvascular cell function. J Appl Physiol (1985). 2023 08 01; 135(2):271-278.
-
Jiang JG, Moore HB, Moore EE, Pieracci F, Sauaia A. Tissue plasminogen activator challenge thrombelastography is the most accurate assay in predicting the need for massive transfusion in hypotensive trauma patients. Am J Surg. 2023 12; 226(6):778-783.
-
Coleman JR, Moore EE, Kelher MR, Jones K, Cohen MJ, Banerjee A, Silliman CC. Elucidating the molecular mechanisms of fibrinolytic shutdown after severe injury: The role of thrombin-activatable fibrinolysis inhibitor. J Trauma Acute Care Surg. 2023 06 01; 94(6):857-862.
-
Moore HB, Saben J, Rodriguez I, Bababekov YJ, Pomposelli JJ, Yoeli D, Ferrell T, Adams MA, Pshak TJ, Kaplan B, Pomfret EA, Nydam TL. Postoperative fibrinolytic resistance is associated with early allograft dysfunction in liver transplantation: A prospective observational study. Liver Transpl. 2023 07 01; 29(7):724-734.
-
Cralley AL, Moore EE, Sauaia A, Carani PH, Schaid TR, DeBot M, Fragoso M, Ghasabyan A, Hansen K, Cohen MJ, Silliman CC, Fox CJ. REBOA for the Treatment of Blast Polytrauma: Zone 3 Provides Cerebral Perfusion, Attenuates Organ Dysfunction and Reperfusion Coagulopathy Compared to Zone 1 in a Swine Model. J Trauma Acute Care Surg. 2023 05 01; 94(5):718-724.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|